He's the favorite bear you can't do without. He's yellow, full of joy and gas a love for honey. Did I mention he is all dressed up for Easter? Yup, you guessed it, today we will be learning how to draw Easter Pooh, step by step. I know a lot of you out there have a love and affection for Winnie the Pooh and that love doesn't go away out of the blue. Here is my version on drawing Winnie the Pooh for Easter and you can do it by following five simple drawing steps. I wanted to make drawing Pooh Bear super simple while adding an Easter flare. I think I accomplished that goal and now all you have to do is use this lesson to draw Easter Pooh for you too. Hey that rhymed! Anyways, go ahead and have some fun. I will be back in a bit with another lesson for you all.


text:
Buffalo Hockey Beat
Free Agency Edition
Early picks give Sabres draft options
BUFFALO – Some of the names you've possibly heard bandied around in trade rumors, the players fans might be drooling about seeing in blue and gold, Sabres general manager Darcy Regier has discussed with his counterparts.
The Sabres, owners of four of the first 44 selections at this weekend's NHL Entry Draft at the Consol Energy Center in Pittsburgh, including picks 12 and 21, have some nice chips if they want to deal.
At this ... Read the full article
Author Bill HoppePosted on 06.19.12 10.19.12 Categories Armia, Boyes, Devine, Ennis, Hecht, Kaleta, McKee, NHL Draft, Pysyk, RegierLeave a comment on Early picks give Sabres draft options
Drew Schiestel was the Sabres' top defense prospect last season. ©2012, Dan Hickling, Olean Times Herald
Sabres loan Schiestel from Amerks
BUFFALO – Last winter, Sabres defense prospect Drew Schiestel earned an AHL All-Star berth.
With 23 points and a gaudy plus-15 rating in Portland, a recall seemed inevitable for the 59th pick in 2007. Then, two games before the big tilt, Schiestel tore his ACL, shelving him for the season.
The 22-year-old hurt his knee again on opening night for Rochester this season, his first appearance in eight months.
On Tuesday, the Sabres loaned ... Read the full article
Author Bill HoppePosted on 03.07.12 11.21.12 Categories Devine, Rochester Americans, SchiestelLeave a comment on Sabres loan Schiestel from Amerks
Categories Select Category Adam (71) Adams (10) Akeson (10) Allen (43) Anaheim Ducks (33) Andreychuk (10) Antipin (88) Arizona Coyotes (43) Armia (55) Asplund (24) Audette (3) Austin (26) Babcock (25) Bagnall (14) Bailey (161) Bales (3) Baptiste (133) Barch (2) Barr (12) Beaulieu (144) Benning (3) Benoit (61) Berglund (45) Bernier (9) Biega (10) Biron (21) Black (30) Blackwell (4) Bodie (4) Bogosian (295) Borgen (24) Boston Bruins (99) Botterill (268) Boucher (6) Boyes (30) Brandon (4) Brennan (66) Briere (36) Brown (1) Bryson (5) Budik (4) Burgdoerfer (14) Bylsma (727) Calgary Flames (30) Campbell (22) Carolina Hurricanes (77) Carrier (68) Cassidy (57) Catenacci (51) Cecconi (8) Cederqvist (2) Chicago Blackhawks (30) Chukarov (2) Cincinnati Cyclones (5) Colaiacovo (76) Colorado Avalanche (40) Columbus Blue Jackets (66) Compher (18) Conacher (29) Connolly (11) Coolen (9) Cornel (25) Corsi (7) Cozens (12) Crawford (5) Criscuolo (39) Crisp (4) Crosby (126) Cunneyworth (27) D'Agostini (36) D'Amigo (20) Dahlin (132) Dallas Stars (44) Dalpe (26) Darling (2) Davidsson (3) Dea (3) Deslauriers (167) Detroit Red Wings (72) Development Camp (71) Devine (22) Dineen (18) Donovan (21) Dougherty (4) Drury (21) Dudley (6) Dupuy (12) Edmonton Oilers (36) Ehrhoff (159) Eichel (808) Elie (54) Ellis (141) Elmira Jackals (3) Ennis (544) Enroth (248) Estephan (9) Europe (32) Falk (119) Fasching (81) Fedun (86) Finley (9) Fitzgerald (5) Florentino (13) Florida Panthers (86) Flynn (137) Foligno (421) Franson (100) French Connection (4) Fuhr (8) Gaustad (23) Gauthier-Leduc (15) Gerbe (92) Gillies (10) Gilmour (3) Gionta (290) Girgensons (425) Glotov (7) Gogulla (2) Gorges (302) Gragnani (15) Granato (2) Grant (46) Greeley (9) Grier (13) Griffith (46) Grigorenko (246) Guhle (106) Hackett (98) Hagel (4) Haim (3) Hajt (11) Halak (21) Hammond (4) Hasek (44) Hawerchuk (10) Hecht (72) Hickey (16) Hodgson (271) Housley (682) Huglen (3) Hunwick (73) Hurley (8) Hutton (100) Irbe (27) Jacobs (6) Jakubowski (4) Jankowski (1) Jeanneret (29) Johansson (19) Johnson (204) Jokiharju (3) Josefson (61) Kaleta (235) Kane (324) Karabacek (21) Kasdorf (35) Kassian (22) Kea (25) Kennedy (14) Klesla (6) Knapp (20) Konopka (54) Kotalik (5) Krueger (20) Kulikov (117) Laaksonen (10) LaFontaine (105) Lalime (1) Lambert (40) Larsson (296) Lazar (4) Leggio (21) Legwand (51) Lehner (417) Leier (5) Leino (195) Lemieux (17) Leopold (81) Lepkowski (6) Lieuwen (70) Lindback (56) Locke (5) Los Angeles Kings (38) Luce (6) Luukkonen (28) Lydman (5) MacArthur (8) MacKenzie (8) Mair (4) Makarov (52) Malarchuk (2) Malkin (36) Malone (30) Mancari (17) Martin (33) Matthews (43) May (5) McBain (64) McCabe (218) McCormick (213) McDavid (117) McGinn (61) McKee (13) McNabb (80) Meszaros (74) Miller (399) Minnesota Wild (54) Mitchell (70) Mittelstadt (116) Mogilny (22) Montador (4) Montour (21) Montreal Canadiens (124) Moore (3) Morrisonn (1) Moulson (315) Murphy (6) Murray (437) Myers (278) Nashville Predators (37) Neale (2) Nelson (133) Neuvirth (120) Nevins (6) New Jersey Devils (62) New York Islanders (65) New York Rangers (74) NHL Draft (130) NHL Lockout (94) NHL Scouting Combine (40) Niedermayer (1) Nilsson (75) Nolan (797) Noronen (4) Novotny (2) Numminen (13) Nylander (107) O'Regan (24) O'Reilly (491) Oglevie (9) Okposo (317) Olofsson (28) Omark (36) Osmanski (10) Ott (258) Ottawa Senators (109) Ovechkin (52) Paetsch (8) Paille (3) Pardy (47) Parker (4) Patrick (22) Payne (14) Pegula (139) Pekar (12) Perreault (36) Persson (3) Peters (7) Petersen (25) Peterson (5) Petrecki (4) Philadelphia Flyers (63) Pilut (66) Pittsburgh Penguins (118) Plante (4) Pominville (375) Porter (94) Portillo (3) Portland Pirates (40) Possler (6) Pouliot (68) Pu (24) Puppa (1) Pysyk (190) Redmond (21) Regehr (67) Regier (244) Reinhart (453) Ristolainen (396) Rivet (3) Robert (6) Rochester Americans (1,216) Rodrigues (214) Rolston (350) Rousek (1) Roy (59) Royce (11) Ruff (282) Ruhwedel (85) Ruotsalainen (3) Sacco (11) Samuels-Thomas (10) Samuelsson (5) San Jose Sharks (37) Sanguinetti (12) Scandella (131) Schaller (76) Schedule (48) Schiestel (11) Schneider (33) Scott (193) Sekera (80) Sexton (25) Sheary (78) Sheppard (7) Skinner (108) Sled Hockey (1) Smith (60) Sobotka (68) Spacek (4) St. Louis Blues (57) Stafford (262) Stephens (12) Stewart (113) Strachan (95) Stuart (2) Sulzer (123) Sundher (7) Szczechura (1) Tallinder (82) Tampa Bay Lightning (78) Tapper (2) Tardif (4) Tarnasky (9) Taylor (54) Tellqvist (3) Tennyson (66) Thompson (84) Toronto Maple Leafs (186) Torres (2) Tropp (61) Trottier (17) Tucker (2) Turgeon (31) Turnbull (9) Ullmark (291) Vancouver Canucks (34) Vanek (273) Varone (66) Vegas Golden Knights (14) Vesey (27) Washington Capitals (69) Weber (264) Wedgewood (20) Weissbach (2) Whitmore (4) Wilcox (20) Willman (5) Wilson (66) Winnipeg Jets (48) Woods (6) Zadorov (163) Zagrapan (2) Zigomanis (7) Zubrus (13)
Buffalo Hockey BeatBeat Coverage of the Buffalo Sabres / © 2019 - Olean Times Herald

redpajama_set_name: RedPajamaCommonCrawl


text:
Body Positive photo exhibition opens
Tue 17 Feb 2015 In: New Zealand Daily News View at Wayback View at NDHA
Body Positive Wellington has opened a special exhibition of images taken by its own supporters. Around 100 people attended the opening at Thistle Hall Gallery in Cuba St last night, with 11 prints selling on opening night. "This project was the brain child of one of Body Positive Wellington's supporters Steve McVey," Body Positive Wellington's Manager Ron Irvine says. "Steve led a group of eight people over a three month period, late last year, teaching them about famous photographers, the different style and techniques each photographer used to come up with great photography. "The themes of each of the sessions were, our environment, self-portraiture, retelling reality, and storytelling. "What made it even more interesting was that we were not allowed to use digital cameras, we had to use disposables. As we know once a shot is taken with a disposable you have that shot. It not like you can erase it and start again" From the total 320 shots taken, each person in the group had to cull their work down to three pictures. Each of these was enlarged and is now on show. The Snapshot Photo exhibition can be seen all this week at Thistle Hall Gallery, 293 Cuba St, Wellington from 10am till 6.30pm. The prints are available for purchase at $60 each. All proceeds will go towards the work done to support services for people living with HIV/AIDS at Body Positive Wellington's centre.
First published: Tuesday, 17th February 2015 - 2:05pm


It seems that Eric Bischoff is having some fun on Twitter by teasing fans on the upcoming Smackdown General Manager role.
The former WCW President has not appeared on WWE live television since December 2007 when he made a special appearance for Raw's 15th Anniversary special. Last year he taped an episodes of Legends with JBL for the WWE Network, a two-hour special that is regarded one of the best interviews on the Network to date. A few weeks ago WWE also released an Eric Bischoff DVD which has some new interviews that Bischoff taped specifically for the release.
Bischoff shocked the wrestling world in 2002 when he was revealed by Vince McMahon as the new General Manager of Monday Night Raw in a surreal segment where Vince hugged Eric on top of the stage, kicking off a WWE career that lasted three years.


text:
Cottage Search
The Silkie Whiskey from Donegal
The Sliabh Liag Distillery will be the first distillery in Donegal for 174 years and their first whiskey is The Silkie – named after the legendary shape-shifting, sea-maidens with long dark hair, deep soulful brown eyes and enchanting voices that were nearly irresistible to any man.
Sliabh Liag Distillery Charter
1. We are reclaiming the distilling heritage of Donegal building a legacy that the whole community are fiercely proud of.
2. We are distillers, this is our home, you are very welcome.
3. We work with courage and conviction and if we don't believe in a job we wont take it on ever.
4. We are resilient and resourceful, we get the job done.
5. We are seanachaí, story tellers that respect lore and build for the long term.
6. We love what we do, sometimes just for the devilment.
Sliabh Liag Distillery
The Sliabh Liag Distillery
View more holiday homes in Carrick
Moville Pier Inishowen
The pier and shorefront area in the seaside village of Moville, Inishowen. Once used as an emigration point, now popular with fishermen and the local rowing club.
Chris Hadfield Space Oddity
During late 2014, Chris Hadfield visited Inishowen and Malin Head to experience Donegal's section of the Wild Atlantic Way and the recent death of David Bowie brought this visit back to mind.
Moville to Greencastle Shore Path
This 3km long path skirts the shores of Lough Foyle between the popular seaside resort of Moville and the fishing village of Greencastle….
Glashedy Rock from Ballyliffin Golf Club
The imposing Glashedy Rock is located in Pollan Bay just of the north Inishowen coastline. If you play either of the 2 courses at Ballyliffin Golf Club, several of the holes have panoramic views over the Bay towards the rock.
Fanad Lighthouse
Fanad Lighthouse is one of 70 lighthouses operated by the Commissioners of Irish Lights around the coast of Ireland and plays a vital role in maritime safety.
Leenan Fort Inishowen
An exploration of an abandoned British military base at Lenan Fort, guarding the mouth of Lough Swilly on the Inishowen peninsula, Donegal, Ireland.
Embrace the Wild Atlantic Way of Life
Leave the ordinary elsewhere this year, and experience the destination that's both thrilling and therapeutic – the Wild Atlantic Way.
The Seaside Village of Rathmullan
Rathmullan, scene of The Flight of the Earls in 1607, is located on the western shores of Lough Swilly and looks across its waters towards the hills of Inishowen.
Arranmore Lighthouse From Above
Arranmore Lighthouse has been in existence since 1859 having replaced the lighthouse built in 1798 which had been de-commissioned in 1832. It is located at Rinrawros Point.
A Love Letter to Donegal
'Atlantic Roar' is a short film shot entirely on the Wild Atlantic Way on the Inishowen Peninsula, Co Donegal – using an entirely local crew. It is a film describing the little things that we would miss about living in Ireland
Cosan an Carria
Sandy Hills Rosapenna
Lag Dubh – Cruit Island
Teach Tráighéanach
1840 Station Cottage
Cottages with Free Wifi
Inishowen Holiday Homes
Visit Donegal Network
Traditional Cottages
Donegal Cottages
A wide and varied selection of holiday homes throughout the north west. Featuring traditional cottages, cottages with wifi, pet friendly accommodation – book directly with owners and benefit from their local knowledge.


text:
Q: How to enable syslog on AIX? I'm trying to enable syslog on AIX. I followed the instructions in this post but it didn't work.
This is my /etc/syslog.conf:
mail.debug      /var/log/mail.log   rotate size 500k files 10
kern.debug      /var/log/kern.log   rotate size 500k files 10
syslog.debug    /var/log/syslog.log rotate size 500k files 10
daemon.debug    /var/log/daemon.log rotate size 500k files 10
local2.debug    /var/log/sudo.log   rotate size 500k files 10

I executed this:
refresh -s syslogd

But nothing is showing up in /var/log
I'm on AIX 6.1.

A: Syslog files must exist before syslogd will write to them.  You will need to touch (as root) the filenames you wish to use first.

touch /var/log/mail.log
touch /var/log/kern.log
...etc

and then refresh syslog

A: If you want to send it to a syslog server as 192.168.1.1
you have to write like this in /etc/syslog.conf
user.info @192.168.1.1 rotate size 100k files 5
syslog.info @192.168.1.1 rotate size 100k files 5
auth.info @192.168.1.1 rotate size 100k files 5
local2.info @192.168.1.1 rotate size 100k files 5

after that don't forget to apply the changes using:
#refresh -s syslogd

redpajama_set_name: RedPajamaStackExchange


text:
Morum bayeri is een slakkensoort uit de familie van de Harpidae. De wetenschappelijke naam van de soort is voor het eerst geldig gepubliceerd in 2001 door Petuch.

Harpidae

redpajama_set_name: RedPajamaWikipedia


Abstract: We study how parental resources early in life affect children's health and education exploiting the so-called speed premium (SP) in the Swedish parental leave system. The SP grants mothers higher parental leave benefits for the subsequent child without re-establishing eligibility through pre-birth market work if the two births occur within a pre-specified interval. This allow us to use a Regression Discontinuity framework. We find that the SP improves the educational outcomes of the first-born child, but not of the second-born. Impacts are driven by a combination of a positive income shock, and substitution from informal care to maternal time.


Could we have a detailed information on the Hal headline.? I could not find any or have I missed it?
It's basically an IIHA 'gift marker' concept presented/developed by Richard Unger, but I recognize it to be a rahter ambiguous concept (which he never defined very well - not suitable at all for proper research in my opnion).
The concept appears to proceed on the (outdated) 'concept' that length of the head line correlates with intelligence... but in the 20th century scientific literature plenty of evidence (which I am not going to summarize here) came available which suggests that this 'concept' is likely not true at all.
People often tend to 'fall in love' with beautiful simple ideas... which often turn out to be illusions when researched properly.
I hope this is helpful anyway.
I fully agree with the view that length of headline does not co-relate to intelligence. I know quite a few people with long headline but very little intellectual ability. I also know 2 advanced computer programmers who make excellent salaries with short headlines.
I'm just curious: do scientific studies use IQ tests as a measure of intelligence ?
Hi Learner, regarding your new question my answer is a simple: yes.
PS. Just curious, why did you wonder about this?
Actually, I was quite sure that they use IQ tests, but I wasn't 100% sure. Scientific research often involves concepts & methods that the common man (such as me) doesn't understand. So I wanted to make sure.
I have occasionally read that IQ tests are not a true measure of intelligence, but I have no idea about the validity of such arguments.
Hence my question. Thanks for the answer.
I have gone through this page earlier. I do not have any strong evidences regarding the co-relation between intelligence and the length of line. According to my understanding Intelligence =IQ + EQ (emotional quotient). IQ is using only one side of the brain, which is not the total human potential and same goes with EQ.
I have found cases of dyslexia, ADHD (Attention deficit hyperactivity disorder) in people with this line. This has got nothing to do with real intelligence. Every person is unique and has unique capabilities which do not find the right stage for their use.I would want to elaborate on this sometime later. Now ADHD is considered to be a psychiatric disorder of the neurodevelopmental type in which there are significant problems with attention, hyperactivity or acting impulsively which is not considered a disorder at all by some other psychiatrists.
Again every intelligent person may have thousands of flaws considered by general standards. All great scientists have been eccentric( scientific study isnt possible without being a bit eccentric).
Now, multi tasking is again thought to be healthy by some and not by others.
One thing I know for sure that Hal headline does seem to give the possessor an analytical brain with multi tasking and data collecting abilities.
After doing some deep thinking and recalling few other hands i had read before, I come to this conclusion that Richard Unger's views about the Hal headline could be partly right ie. about the analytic mind, data collecting, multi-tasking but not about being a mega computer as this needs support from other signs and lines.
This line alone cannot make a person intelligent. True intelligence needs the support of other marks and lines. According to the studies on emotional and intellectual intelligence, more importance is given to the EQ. People who are emotionally intelligent know the difference between what's important to them and what is important to someone else,and also know the difference between what they need to survive and a passing whim.They can weather life's thousands of setbacks. They have a sense of proportion which the brainiest among us often lose.
The hands I studied were of 2 women one almost 70 and the other in her forties. The former was a writer,had a deep study in literature and language,was successful for a short period, multi talented, multitasker but due to lack of E.I., did not prioritize her children.
So I do agree about the intelligence part. . Nothing more to comment.


One of the most difficult things to understand about suicide prevention is how big of a difference it can make to reduce the means of committing suicide in your home. The difference between the availability of lethal means during a suicidal crisis can be the difference between life and death.
Thankfully, you do not need to understand all of the complexities of how Means Reduction can help prevent suicides in order to suicide proof your home. All you need is around $21.
You can get the Master Lock Gun Lock recommended by Montana's Suicide Prevention Coordinator Karl Rosston and a Vaultz Medicine Case for $20.94 plus shipping and handling.
While locking up guns and medications will not entirely reduce the danger of suicide, it's an incredibly powerful step to help avoid tragedy.


Restaurant in the hotel - not uncommon, but still better when the hotel with the possibility of breakfast, lunch and dinner in one place. Explore our selection of hotels in Antigua And Barbuda and book without leaving home. The average price of a hotel Antigua And Barbuda to the restaurant for one night starts at $107 and reaches $999, and the rating of 9.2 points out of 10.


Last year, we fell in love with an Italian brand called the Velvet Room. Designer Alessandra Di Ioia has crafted a gorgeous collection of lingerie. Every piece in her collection is handmade and known for its vintage, romantic and feminine style and are made from quality silk, cotton and satin enriched by ribbons, laces and pearls.
What made you decide to go into Lingerie? Did you always want to be a lingerie designer?
It's all began a few years ago when I was involved in organizing a swap business. I used to recycle fabric stocks reinventing clothing deemed "no longer fashionable". Slowly, I started experimenting with some lingerie designs. After a while of tinkering, I found myself with a few unique pieces. I showed them around and had many requests for more. That's how the first the Velvet Room collection was born. Before that, I'd never thought about becoming a lingerie designer, but I realized then that I really love lingerie!
Did you already come from a fashion background when you decided to create your own brand?
I actually didn't start in a fashion background. My background was in the humanities. In school, I started with with a modern literature degree and then graduated with a human resources master's degree. My brand was born when I lost my job and decided to run with the Velvet Room. That decision helped give me a new chance in my life.
How did you come to decide on the name, The Velvet Room? What meaning does it hold for you?
The word "Velvet" suggests to me something soft, delicate, embracing and fascinating. In my mind, it's one of the best words to suggest femininity.
How long did it take to get the Velvet Room up and running? Who was the first boutique to carry your collection?
It took about three months to get things started with the website and the Facebook page. The first boutique that gave me the chance was a shop here in Italy that picked up only few items at the start. But it was an exhilarating start and those few pieces in that boutique meant so much for me!
As an artist/designer, where do you look for inspiration?
Everywhere! Beauty and art surrounds us!
What are some lingerie brands or designers that you find inspiring and/or exciting?
I really like the American designer, Clare Bare! She's talented and her brand grows day-by-day! I also love Damaris and Lejaby – lovely!
We know that it's not easy being an independent designer. A lot of designers wear a lot of hats running their own brand/business from designing to running their own social media campaigns, do you have some help or are you also doing it all on your own?
I make everything on my own and pretty much juggle everything from social media to the accounting. I feel that it's a shame that there isn't more help for independent designers…Smaller brands offer something new and different and we are not commercial. We don't follow the global rules and preconceptions about what lingerie should be about. I think that this perspective has to be underlined!
What do you do for fun when you're not designing and running your own business?
My job takes up so much of my time but when I am free from the Velvet Room, I try to spend time with the people I love, taking some "me" time and work on some other retail projects that I'm involved with.
One of the things that stands out in your collection is the ecofriendly range. Why is creating Eco-Friendly Lingerie important for you?
I think that's important because of the chance of re-use something you really care about! Discarded clothes and fabrics that you still care about are re-invented and transformed into something new. The added benefit is that in that way you have the chance to own a new, exclusive and original lingerie product created following your tastes and preferences!
Untitled from The Velvet Room on Vimeo.
You put a lot creativity into your photoshoots and videos, could you tell us a little bit more about how you plan and execute your marketing? Do you do it all yourself?
Thank you! The amazing photoshoots are realized in collaboration with a famous photographer, Gianluca Adovasio! We love to working together! My main role when we work together is to do the styling on the shoots.
What's next for the Velvet Room? Are you doing any trade shows? Events?
I hope to grow my brand starting with the next collection by including homewear and swimwear. I also would like to enrich the Velvet Room's lingerie by employing more traditional Italian manufacturing.
At the moment I'm looking for a collaboration! And a very secret event is almost ready to promote the spring summer collection! Stay tuned!
For our readers that want to learn more about your collection, where should we point them to? What if they have some wholesale questions, how can they contact you?
It is possible to learn more about and also to purchase the new The Velvet Room collection on the offìcial website: www.thevelvetroom.it or in the associated online stores.
Customers can also find us on our Offìcial Facebook Page and Twitter page.


text:
Reading: Man's sexual engagement with his mother in Kwara results in 3 children
INSIDE NEWS > Blog > TOP NEWS > Man's sexual engagement with his mother in Kwara results in 3 children
Man's sexual engagement with his mother in Kwara results in 3 children
Adamu Sime and Mother
Continual sexual engagement between a Kwara State-based man and his mother has produced three children.
The man's brother is also said to be having carnal knowledge of her.
According to the News Agency of Nigeria, the command's spokesman, Mr Babawale Afolabi, confirmed this in a statement he signed and made available to the News Agency of Nigeria (NAN) on Sunday, in Ilorin.
Afolabi said that Sime had been having an affair with his mother for a long time and it had resulted in three offspring.
READ ALSO: Stella Oduah Dumps PDP, Joins APC
"On Sept. 9, the District Head of Mosne Had Community, Kaima, Malam Bandede, reported the forbidden act being committed by Sime and his mother Fati Sime of the same community.
"Men from the Intelligence Unit, NSCDC in Kaima, swung into action and the outcome of the investigations established the fact that the mother (Fati) had birthed three children for her biological son", he stated.
Afolabi said that further investigation revealed that the younger brother of the accused, who was also confirmed to be sleeping with the mother, was now at large.
He said that the mother and her two sons did not have the necessary papers to stay in Nigeria and had been handed over to the Nigeria lmmigration Service, for background checks and further action.
TAGGED: children, INSIDE, life, mother, sex, sex education, sexual harrasment
Once more, Fancy Acholonu and Alexx Ekubo break up.
Uruguay defeat Ghana, both teams out of World Cup
Anambra businessman found dead in Bauchi hotel


Snowboards.com offers a very large selection of women's snowboarding pants in different styles, cuts, materials and more. So, just how exactly are you supposed to best select a pair of women's snowboard pants when there are so many to choose from? Here we are going to go over some of the main differences in these pants and how you can use our website to narrow down and easily shop these pants to ensure you are making the best selection possible.
If you look to the left side of the page you will see a bunch of refinement boxes where you can select several different refinements to narrow down your search. The first couple of boxes are brand, color and size. These are going to be the most commonly used refinements when shopping women's snowboard pants. You can easily select a certain brand, color or size of pant you are looking for. If you know you take snowboard pants in a size medium than you can simply select medium in the size refinement box and the page will refresh only showing pants in the size medium. Same with brand and color, making these selections will refresh the page to show these specifics. These refinements work great if you are shopping women's snowboard pants as a gift as you can easily search for a certain color or brand making your choice easier.
Depending on the level of snowboarding you plan on doing, how often you are going and the climate of where you snowboard you will need differing snowboard pants. With so many women's snowboard pants to select from it's nice to be able to narrow down your selection by type of pants, technology used in the pants and features found on the pants.
There are a few main types of women's snowboarding pants you will encounter; these types are insulated, shell or a combination of insulated and shell. Insulated pants are the most common and will keep you the warmest, shell snowboard pants offer a thin and lightweight design but will require more layering beneath them on colder days. A combination women's snowboard pant, often called a 3 in 1 will offer a shell outer with a removable shell inner. These combination pants are the least common but can be great for those in a varying climate.
There are two main technologies to pay attention to when shopping women's snowboard pants; those technologies are waterproofing and breathability. You can search pants narrowed down by this technology so you know you are getting pants that are up to your standards.
Shopping for women's pants with a certain feature has never been easier; on the left of the page in the refinements you will find refinements for suspenders, number of pockets, thigh zip venting and more. If you are looking for pants with a certain feature be sure to spend some time checking these features.


text:
'use strict';

angular.module('YQuiz')
    .service('quizService', quizService);

function quizService(API, $http, $q) {
    var quizGetAll = function (page) {
        return $http.get(API.URL + 'quizzes?sort=-_id&page=' + page);
    };

    var quizGetOne = function (slug) {
        return $http.get(API.URL + 'quizzes?slug=' + slug);
    };

    var questionByQuiz = function (id) {
        return $http.get(API.URL + 'questions?quiz=' + id);
    };

    var resultByQuiz = function (id) {
        return $http.get(API.URL + 'results?quiz=' + id);
    };

    var uploadPhoto = function (formData) {
        return $http.post(API.URL + 'photos', formData)
            .then(function (res) {
                if (typeof res.data === 'object') {
                    return res.data;
                } else {
                    // invalid response
                    return $q.reject(res.data);
                }
            }, function(res) {
                return $q.reject(res.data);
            })
    };

    var quizCreate = function (formData) {
        return $http.post(API.URL + 'quizzes', formData)
    };

    return {
        quizGetAll: quizGetAll,
        quizGetOne: quizGetOne,
        questionByQuiz: questionByQuiz,
        resultByQuiz: resultByQuiz,
        quizCreate: quizCreate,
        uploadPhoto: uploadPhoto
    }
}

redpajama_set_name: RedPajamaGithub


What he's done for us lately: The Florida Stage has stuck by its guns for 17 years, producing quality new stage works with professionalism. No tired revivals of Arsenic and Old Lace or The Glass Menagerie, no janitors stumbling on as walk-ons, no costumes from Kmart. Spots are hit, lines are spoken on cue, and the company does its damnedest to grapple with the issues that contemporary playwrights are brooding upon. This year, Tyrrell, a hands-on theater man all the way, directed local playwright Michael McKeever's macabre Running with Scissors. Then the company staged one of the best South Florida productions of the past year, Permanent Collection, Thomas Gibbons' challenging examination of institutional racism and political correctness.
What it takes: "In the theater, it's all about collaboration. The thing that's driven me is ultimately a practical need to interact with other people, to have a positive impact on the community in the small way that we do. The moment we start to think too much of ourselves and that impact, though, I remind myself that we wear wigs and bows for a living."


Once acquiring that first million — so we're told — the thirst for the finer things in life intensifies. This appetite isn't solely satisfied by high-priced cars and luxury fashion, however, as now, the worlds of cryptocurrency and streetwear have begun to mingle in a major way.
For example, GQ recently sat down with 19-year-old Erik Finman, Bitcoin millionaire. While detailing his start in Bitcoin investing, Finman also tells of his affinity for streetwear.
Initially, Finman was drawn in by Kanye West's adidas YEEZY line, alongside various BAPE products. This all ultimately led to one brand that should come as no surprise, Supreme. He quickly realized his obsession was getting out of hand, though, specifically prior to the release of Supreme's uber-coveted Louis Vuitton collaboration.
For more on this group of cryptocurrency kids and their love of streetwear, follow on over to GQ.
In related news, it's recently come out that 50 Cent is secretly a Bitcoin millionaire.


text:
Irish Jokes and Puns
Here are funny Irish jokes and puns. Irish people have a funny and sometimes crude sense of humor. Perfect to share on St Patricks Day. Make sure to also check out our other jokes categories.
Funny Irish Joke – 10
Try to say "Irish wristwatch"
Funny Irish Joke – 1
An Irish priest is driving along a country road when a police man pulls him over. He immediately smells alcohol on the priest's breath and notices an empty wine bottle in the car.
He says: "Have you been drinking?"
"Just water," says the priest.
The cop replies: "Then why do I smell wine?"
The priest looks at the bottle and says: "Good Lord! He's done it again!"
Paddy and Mick are walking down the road and Paddy has a bag of doughnuts in his hand.
Paddy says to Mick: "If you can guess how many doughnuts are in my bag, you can have them both."
Mick and Paddy are walking along when Mick falls down a manhole. Paddy shouts down: "What shall I do?" Mick barks back: "Call me an ambulance!"
Paddy then jumps up and down screaming: "Mick is an ambulance, Mick is an ambulance."
An English man, Irish man, Scotch man are in a desert, they got captured by the Germans. The Germans say, I will give you one thing before you die. The Englishman man say water, the Scotch man say whiskey, the Irish man says a car door. The Germans say, why do you want a car door. The Irish man says, because when it gets hot, it can wind down the window.
An Irishman is struggling to find a parking space.
"Lord," he prayed. "I can't stand this. If you open a space up for me, I swear I'll give up the Guinness and go to mass every Sunday."
Suddenly, the clouds part and the sun shines on an empty parking spot. Without hesitation, the Irishman says: "Never mind, I found one!"
How many Irishmen does it take to screw in a lightbulb?
Six. One to hold the bulb and five others to stand around and drink until the room spins.
Funny Alcohol Joke – 3
An Irishman, Englishman and Scotsman go into a pub and each order a pint of Guinness. Just as the bartender hands them over, three flies buzz down and one lands in each of the pints. The Englishman looks disgusted, pushes his pint away and demands another pint. The Scotsman picks out the fly, shrugs, and takes a long swallow. The Irishman reaches in to the glass, pinches the fly between his fingers and shakes him while yelling, "Spit it out, ya bastard! Spit it out!"
Two Irishmen were driving home one night from the pub when one asked the other to check if the car's indicators are working.
He promptly sticks his head out the window and says: "Yes,no,yes,no,yes,no,yes,no"
Two Irishmen were working in the public works department. One would dig a hole and the other would follow behind him and fill the hole in.
After a while, one amazed onlooker said: "Why do you dig a hole, only to have your partner follow behind and fill it up again?"
The hole digger wiped his brow and sighed, "Well, I suppose it probably looks odd because we're normally a three-person team. But today the lad who plants the trees called in sick."
The local District Judge had given the defendant a lecture on the evils of drink. But in view of the fact that this was the first time the man had been drunk and incapable, the case was dismissed on payment of ten shillings costs. "Now don't let me ever see your face again," said the Justice sternly as the defendant turned to go. "I'm afraid I can't promise that, sir," said the released man. "And why not?" Because I'm the barman at your regular pub!
I've got my own recipe for Irish stew: Get some meat, some potatoes and a lot of Guinness Stout. Drink all of the beer. Forget about the stew.


text:
Biomarkers /
Back to Biomarkers List
Associated Genetic Biomarkers
KRAS G12A
KRAS G12C
KRAS G12D
KRAS G12R
KRAS A146P
KRAS A146T
KRAS A146V
KRAS G12S
KRAS G12V
KRAS K117N
KRAS Mutation
KRAS Q61H
KRAS Q61K
KRAS Q61L
KRAS Q61P
KRAS Q61R
KRAS A11_G12dup
KRAS A146S
KRAS A59E
KRAS A59G
KRAS A59P
KRAS A59S
KRAS A59T
KRAS A59V
KRAS Amplification
KRAS Codon 12 Missense
KRAS Codon 146 Missense
KRAS D119N
KRAS D33E
KRAS Exon 2 Mutation
KRAS F156L
KRAS F28L
KRAS G10dup
KRAS G12F
KRAS G12L
KRAS G13E
KRAS K147E
KRAS K5N
KRAS L19F
KRAS Mutation (somatic)
KRAS N116S
KRAS P34L
KRAS P34R
KRAS Q22E
KRAS T58I
KRAS T74P
KRAS V14I
KRAS V14L
KRAS Y71H
Associated Diseases
Juvenile Myelomonocytic Leukemia
Colon Carcinoma
Rectal Carcinoma
Prostate Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma
Thyroid Gland Adenocarcinoma
Colorectal Carcinoma
Lung Carcinoma
Malignant Solid Tumor
Thymic Carcinoma
Bladder Carcinoma
Colorectal Adenocarcinoma
Rhabdoid Tumor
Head and Neck Carcinoma
Pancreatic Carcinoma
Myelodysplastic/Myeloproliferative Neoplasm
Head and Neck Squamous Cell Carcinoma
Histiocytic and Dendritic Cell Neoplasm
Pancreatic Ductal Adenocarcinoma
Adenocarcinoma of the Gastroesophageal Junction
Thyroid Gland Follicular Carcinoma
Thyroid Gland Papillary Carcinoma
Lung Adenocarcinoma
Associated Pathways
MAP kinase signaling
Location [1]
12p12.1
Protein [2]
GTPase KRas, N-terminally processed
Synonyms [1]
KRAS1, K-RAS4A, RASK2, C-K-RAS, KRAS2, K-RAS2A, CFC2, NS, RALD, KI-RAS, K-RAS4B, c-Ki-ras2, K-RAS2B, NS3
KRAS (Kirsten rat sarcoma viral oncogene homolog) encodes for the GTPase KRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. KRAS is implicated in the pathogenesis of several cancers.
KRAS is altered in 15.66% of all cancers with colorectal adenocarcinoma, non-small cell lung carcinoma, pancreatic exocrine neoplasm, uterine corpus neoplasm, and ovarian neoplasm having the greatest prevalence of alterations [3].
KRAS GENIE Cases - Top Diseases
The most common alterations in KRAS are KRAS Mutation (20.55%), KRAS Mutation (germline) (20.55%), KRAS Mutation (somatic) (20.55%), KRAS Codon 12 Missense (15.92%), and KRAS G12D (5.57%) [3].
KRAS GENIE Cases - Top Alterations
Biomarker-Directed Therapies
View Therapies for KRAS
KRAS is a predictive biomarker for use of cetuximab, panitumumab, afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib in patients.
Non-small cell lung carcinoma and colorectal carcinoma have the most therapies with KRAS as a predictive biomarker.
Of the therapies with KRAS as a predictive biomarker, 2 are FDA-approved in at least one clinical setting and 7 have NCCN guidelines in at least one clinical setting.
KRAS A11_G12dup, KRAS A146P, KRAS A146S, KRAS A146T, and KRAS A146V are the top alterations on KRAS targeted by therapies [4].
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following:
Sensitizing EGFR Mutations
KRAS Resistance Mutations
Predicted Response: Primary Resistance
Clinical Setting(s): Metastatic (NCCN)
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy.
Clinical Setting(s): Metastatic (NCCN, MCG)
Cetuximab +
Colorectal Carcinoma -
NRAS/KRAS Resistance Mutations for Panitumumab and Cetuximab in CRC
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO)
KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS A146P, KRAS A146T, KRAS A146V, KRAS G12S, KRAS G12V, KRAS G13A, KRAS G13C, KRAS G13D, KRAS G13R, KRAS G13S, KRAS G13V, KRAS K117N, KRAS Q61H, KRAS Q61K, KRAS Q61L, KRAS Q61P, KRAS Q61R, NRAS G12A, NRAS G12C, NRAS G12D, NRAS G12S, NRAS G12V, NRAS Q61K, NRAS Q61R
Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO)
KRAS A11_G12dup, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS G60E
Predicted Response: Theoretical Primary Resistance
Clinical Setting(s): Metastatic (MCG)
Note: Preclinical studies and limited retrospective data suggest that KRAS amplification confers resistance to anti-EGFR antibodies.
Dacomitinib +
Erlotinib +
Gefitinib +
Osimertinib +
EGFR T790M
Sensitizing EGFR Mutations (NCCN)
Panitumumab +
View Clinical Trials for KRAS
KRAS status serves as an inclusion eligibility criteria in 120 clinical trials, of which 97 are open and 23 are closed. Of the trials that contain KRAS status as an inclusion criterion, 49 are phase 1 (36 open), 30 are phase 1/phase 2 (28 open), 36 are phase 2 (28 open), and 5 are phase 3 (5 open).
Trials with KRAS status in the inclusion eligibility criteria most commonly target malignant solid tumor, non-small cell lung carcinoma, colorectal carcinoma, acute myeloid leukemia, and colorectal adenocarcinoma [4].
Trials Investigating KRAS by Disease and Recruiting Status
The most frequent alterations to serve as inclusion eligibility criteria are KRAS Mutation, KRAS G12C, KRAS G12D, KRAS G12R, and KRAS G12V [4].
Trials Investigating KRAS by Alteration and Recruiting Status
Trametinib, selumetinib, binimetinib, abemaciclib, and erlotinib are the most frequent therapies in trials with KRAS as an inclusion criteria [4].
Drugs Being Investigated in KRAS Trials by Recruiting Status
Significance of KRAS in Diseases
Non-Small Cell Lung Carcinoma +
KRAS is mutated in 29.7% of non-small cell lung carcinoma patients [3].
KRAS is an inclusion criterion in 43 clinical trials for non-small cell lung carcinoma, of which 35 are open and 8 are closed. Of the trials that contain KRAS status and non-small cell lung carcinoma as inclusion criteria, 19 are phase 1 (15 open), 8 are phase 1/phase 2 (8 open), 12 are phase 2 (8 open), and 4 are phase 3 (4 open) [4].
Erlotinib, pemetrexed, and abemaciclib are the most frequent therapies in non-small cell lung carcinoma trials with KRAS alterations as inclusion criteria [4].
Malignant Solid Tumor +
KRAS is mutated in 3.3% of malignant solid tumor patients [3].
KRAS is an inclusion criterion in 43 clinical trials for malignant solid tumor, of which 36 are open and 7 are closed. Of the trials that contain KRAS status and malignant solid tumor as inclusion criteria, 24 are phase 1 (17 open), 11 are phase 1/phase 2 (11 open), and 8 are phase 2 (8 open) [4].
Selumetinib, olaparib, and everolimus are the most frequent therapies in malignant solid tumor trials with KRAS alterations as inclusion criteria [4].
Colorectal Carcinoma +
KRAS is mutated in 47.01% of colorectal carcinoma patients [3].
KRAS is an inclusion criterion in 25 clinical trials for colorectal carcinoma, of which 23 are open and 2 are closed. Of the trials that contain KRAS status and colorectal carcinoma as inclusion criteria, 14 are phase 1 (13 open), 8 are phase 1/phase 2 (8 open), and 3 are phase 2 (2 open) [4].
Trametinib, cetuximab, and binimetinib are the most frequent therapies in colorectal carcinoma trials with KRAS alterations as inclusion criteria [4].
Acute Myeloid Leukemia +
KRAS is mutated in 3.77% of acute myeloid leukemia patients [3].
KRAS is an inclusion criterion in 10 clinical trials for acute myeloid leukemia, of which 6 are open and 4 are closed. Of the trials that contain KRAS status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [4].
Binimetinib, busulfan, and fludarabine are the most frequent therapies in acute myeloid leukemia trials with KRAS alterations as inclusion criteria [4].
Pancreatic Carcinoma +
KRAS is mutated in 86.05% of pancreatic carcinoma patients [3].
KRAS is an inclusion criterion in 7 clinical trials for pancreatic carcinoma, of which 7 are open and 0 are closed. Of the trials that contain KRAS status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [4].
Extended release flucytosine, trail receptor agonist abbv-621, and valproic acid are the most frequent therapies in pancreatic carcinoma trials with KRAS alterations as inclusion criteria [4].
Colorectal Adenocarcinoma +
KRAS is mutated in 44.19% of colorectal adenocarcinoma patients [3].
KRAS is an inclusion criterion in 7 clinical trials for colorectal adenocarcinoma, of which 5 are open and 2 are closed. Of the trials that contain KRAS status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].
Anti-gpa33/cd3 monoclonal antibody mgd007, gm-csf, and tg02 are the most frequent therapies in colorectal adenocarcinoma trials with KRAS alterations as inclusion criteria [4].
Myelodysplastic Syndromes +
KRAS is mutated in 1.35% of myelodysplastic syndromes patients [3].
KRAS is an inclusion criterion in 7 clinical trials for myelodysplastic syndromes, of which 5 are open and 2 are closed. Of the trials that contain KRAS status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Allogeneic hematopoietic stem cell transplantation, busulfan, and fludarabine are the most frequent therapies in myelodysplastic syndromes trials with KRAS alterations as inclusion criteria [4].
Pancreatic Ductal Adenocarcinoma +
KRAS is mutated in 80.0% of pancreatic ductal adenocarcinoma patients [3].
KRAS is an inclusion criterion in 6 clinical trials for pancreatic ductal adenocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open) and 1 is phase 2 (1 open) [4].
Asn007, dendritic cell vaccine, and erk1/2 inhibitor ly3214996 are the most frequent therapies in pancreatic ductal adenocarcinoma trials with KRAS alterations as inclusion criteria [4].
Non-Hodgkin Lymphoma +
KRAS is mutated in 3.6% of non-hodgkin lymphoma patients [3].
KRAS is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].
Ulixertinib, selumetinib, and antineoplastic immune cell are the most frequent therapies in non-hodgkin lymphoma trials with KRAS alterations as inclusion criteria [4].
Chronic Myelomonocytic Leukemia +
KRAS is mutated in 12.0% of chronic myelomonocytic leukemia patients [3].
KRAS is an inclusion criterion in 5 clinical trials for chronic myelomonocytic leukemia, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Busulfan, fludarabine, and allogeneic cd56-positive cd3-negative natural killer cells are the most frequent therapies in chronic myelomonocytic leukemia trials with KRAS alterations as inclusion criteria [4].
Melanoma +
KRAS is mutated in 3.03% of melanoma patients [3].
KRAS is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and melanoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [4].
Asn007, erk1/2 inhibitor ly3214996, and extended release flucytosine are the most frequent therapies in melanoma trials with KRAS alterations as inclusion criteria [4].
Breast Carcinoma +
KRAS is mutated in 1.92% of breast carcinoma patients [3].
KRAS is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Extended release flucytosine, vistusertib, and abemaciclib are the most frequent therapies in breast carcinoma trials with KRAS alterations as inclusion criteria [4].
Multiple Myeloma +
KRAS is an inclusion criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].
Trametinib, antineoplastic immune cell, and raf/mek serine/threonine kinase inhibitor ro5126766 are the most frequent therapies in multiple myeloma trials with KRAS alterations as inclusion criteria [4].
Acute Lymphoblastic Leukemia +
KRAS is mutated in 9.87% of acute lymphoblastic leukemia patients [3].
KRAS is an inclusion criterion in 4 clinical trials for acute lymphoblastic leukemia, of which 4 are open and 0 are closed. Of the trials that contain KRAS status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [4].
Antineoplastic immune cell, ect-001 expanded cord blood, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute lymphoblastic leukemia trials with KRAS alterations as inclusion criteria [4].
Squamous Cell Lung Carcinoma +
KRAS is mutated in 5.35% of squamous cell lung carcinoma patients [3].
KRAS is an inclusion criterion in 4 clinical trials for squamous cell lung carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (0 open) [4].
Antroquinonol capsule, auranofin, and vistusertib are the most frequent therapies in squamous cell lung carcinoma trials with KRAS alterations as inclusion criteria [4].
Glioma +
KRAS is mutated in 0.81% of glioma patients [3].
KRAS is an inclusion criterion in 4 clinical trials for glioma, of which 4 are open and 0 are closed. Of the trials that contain KRAS status and glioma as inclusion criteria, 4 are phase 1/phase 2 (4 open) [4].
Cobimetinib and trametinib are the most frequent therapies in glioma trials with KRAS alterations as inclusion criteria [4].
Ovarian Carcinoma +
KRAS is mutated in 11.36% of ovarian carcinoma patients [3].
KRAS is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].
Extended release flucytosine, sra737, and vistusertib are the most frequent therapies in ovarian carcinoma trials with KRAS alterations as inclusion criteria [4].
Cancer +
KRAS is mutated in 6.57% of cancer patients [3].
KRAS is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and cancer as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Head And Neck Squamous Cell Carcinoma +
KRAS is mutated in 2.38% of head and neck squamous cell carcinoma patients [3].
KRAS is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Ko-947 and sra737 are the most frequent therapies in head and neck squamous cell carcinoma trials with KRAS alterations as inclusion criteria [4].
Neurofibromatosis Type 1 +
KRAS is an inclusion criterion in 3 clinical trials for neurofibromatosis type 1, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and neurofibromatosis type 1 as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].
Azacitidine and trametinib are the most frequent therapies in neurofibromatosis type 1 trials with KRAS alterations as inclusion criteria [4].
Colon Carcinoma +
KRAS is mutated in 43.13% of colon carcinoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for colon carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Valproic acid and neratinib are the most frequent therapies in colon carcinoma trials with KRAS alterations as inclusion criteria [4].
Lung Adenocarcinoma +
KRAS is mutated in 32.99% of lung adenocarcinoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Ponatinib and trametinib are the most frequent therapies in lung adenocarcinoma trials with KRAS alterations as inclusion criteria [4].
Esophageal Carcinoma +
KRAS is mutated in 13.13% of esophageal carcinoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Palbociclib is the most frequent therapy in esophageal carcinoma trials with KRAS alterations as inclusion criteria [4].
Bladder Carcinoma +
KRAS is mutated in 6.76% of bladder carcinoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in bladder carcinoma trials with KRAS alterations as inclusion criteria [4].
Small Cell Lung Carcinoma +
KRAS is mutated in 3.97% of small cell lung carcinoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, auranofin, and erlotinib are the most frequent therapies in small cell lung carcinoma trials with KRAS alterations as inclusion criteria [4].
Diffuse Large B-Cell Lymphoma +
KRAS is mutated in 1.49% of diffuse large B-cell lymphoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, trail receptor agonist abbv-621, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in diffuse large B-cell lymphoma trials with KRAS alterations as inclusion criteria [4].
Renal Cell Carcinoma +
KRAS is mutated in 1.07% of renal cell carcinoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Vistusertib, cabozantinib, and docetaxel are the most frequent therapies in renal cell carcinoma trials with KRAS alterations as inclusion criteria [4].
Neuroblastoma +
KRAS is mutated in 0.93% of neuroblastoma patients [3].
KRAS is an inclusion criterion in 2 clinical trials for neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in neuroblastoma trials with KRAS alterations as inclusion criteria [4].
Rectal Carcinoma +
KRAS is mutated in 41.92% of rectal carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Endometrial Carcinoma +
KRAS is mutated in 20.89% of endometrial carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in endometrial carcinoma trials with KRAS alterations as inclusion criteria [4].
Cholangiocarcinoma +
KRAS is mutated in 16.45% of cholangiocarcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Vistusertib, adavosertib, and capivasertib are the most frequent therapies in cholangiocarcinoma trials with KRAS alterations as inclusion criteria [4].
Lung Carcinoma +
KRAS is mutated in 11.93% of lung carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Vitamin c supplement is the most frequent therapy in lung carcinoma trials with KRAS alterations as inclusion criteria [4].
Germ Cell Tumor +
KRAS is mutated in 16.67% of germ cell tumor patients [3].
KRAS is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Palbociclib is the most frequent therapy in germ cell tumor trials with KRAS alterations as inclusion criteria [4].
Adenocarcinoma Of The Gastroesophageal Junction +
KRAS is mutated in 13.1% of adenocarcinoma of the gastroesophageal junction patients [3].
KRAS is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [4].
Docetaxel and selumetinib are the most frequent therapies in adenocarcinoma of the gastroesophageal junction trials with KRAS alterations as inclusion criteria [4].
Malignant Ovarian Epithelial Tumor +
KRAS is mutated in 11.95% of malignant ovarian epithelial tumor patients [3].
KRAS is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Paclitaxel and spleen tyrosine kinase inhibitor tak-659 are the most frequent therapies in malignant ovarian epithelial tumor trials with KRAS alterations as inclusion criteria [4].
Gastric Carcinoma +
KRAS is mutated in 11.87% of gastric carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Palbociclib is the most frequent therapy in gastric carcinoma trials with KRAS alterations as inclusion criteria [4].
Gastric Adenocarcinoma +
KRAS is mutated in 11.72% of gastric adenocarcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].
Docetaxel and selumetinib are the most frequent therapies in gastric adenocarcinoma trials with KRAS alterations as inclusion criteria [4].
Urothelial Carcinoma +
KRAS is mutated in 6.22% of urothelial carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Carcinoma +
KRAS is mutated in 5.03% of thyroid gland carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with KRAS alterations as inclusion criteria [4].
Malignant Peripheral Nerve Sheath Tumor +
KRAS is mutated in 5.0% of malignant peripheral nerve sheath tumor patients [3].
KRAS is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in malignant peripheral nerve sheath tumor trials with KRAS alterations as inclusion criteria [4].
Papillary Renal Cell Carcinoma +
KRAS is mutated in 4.31% of papillary renal cell carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in papillary renal cell carcinoma trials with KRAS alterations as inclusion criteria [4].
Poorly Differentiated Thyroid Gland Carcinoma +
KRAS is mutated in 4.31% of poorly differentiated thyroid gland carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in poorly differentiated thyroid gland carcinoma trials with KRAS alterations as inclusion criteria [4].
Thyroid Gland Adenocarcinoma +
KRAS is mutated in 4.07% of thyroid gland adenocarcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for thyroid gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Iodine i-124 fiau, iodine i-131, and trametinib are the most frequent therapies in thyroid gland adenocarcinoma trials with KRAS alterations as inclusion criteria [4].
Mantle Cell Lymphoma +
KRAS is mutated in 3.7% of mantle cell lymphoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in mantle cell lymphoma trials with KRAS alterations as inclusion criteria [4].
Anaplastic Astrocytoma +
KRAS is mutated in 2.99% of anaplastic astrocytoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in anaplastic astrocytoma trials with KRAS alterations as inclusion criteria [4].
Rhabdomyosarcoma +
KRAS is mutated in 4.31% of rhabdomyosarcoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in rhabdomyosarcoma trials with KRAS alterations as inclusion criteria [4].
Histiocytic And Dendritic Cell Neoplasm +
KRAS is mutated in 2.44% of histiocytic and dendritic cell neoplasm patients [3].
KRAS is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Selumetinib is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with KRAS alterations as inclusion criteria [4].
Thyroid Gland Follicular Carcinoma +
KRAS is mutated in 2.15% of thyroid gland follicular carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in thyroid gland follicular carcinoma trials with KRAS alterations as inclusion criteria [4].
Thyroid Gland Papillary Carcinoma +
KRAS is mutated in 2.02% of thyroid gland papillary carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in thyroid gland papillary carcinoma trials with KRAS alterations as inclusion criteria [4].
Lymphoma +
KRAS is mutated in 1.64% of lymphoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in lymphoma trials with KRAS alterations as inclusion criteria [4].
Sarcoma +
KRAS is mutated in 1.87% of sarcoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in sarcoma trials with KRAS alterations as inclusion criteria [4].
Chronic Myeloid Leukemia +
KRAS is mutated in 1.47% of chronic myeloid leukemia patients [3].
KRAS is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Allogeneic cd56-positive cd3-negative natural killer cells, interleukin-2, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in chronic myeloid leukemia trials with KRAS alterations as inclusion criteria [4].
Head And Neck Carcinoma +
KRAS is mutated in 2.06% of head and neck carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in head and neck carcinoma trials with KRAS alterations as inclusion criteria [4].
Soft Tissue Sarcoma +
KRAS is mutated in 1.85% of soft tissue sarcoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in soft tissue sarcoma trials with KRAS alterations as inclusion criteria [4].
Glioblastoma +
KRAS is mutated in 1.67% of glioblastoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in glioblastoma trials with KRAS alterations as inclusion criteria [4].
Prostate Carcinoma +
KRAS is mutated in 1.1% of prostate carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Sra737 is the most frequent therapy in prostate carcinoma trials with KRAS alterations as inclusion criteria [4].
Gastrointestinal Stromal Tumor +
KRAS is mutated in 0.68% of gastrointestinal stromal tumor patients [3].
KRAS is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in gastrointestinal stromal tumor trials with KRAS alterations as inclusion criteria [4].
Hepatocellular Carcinoma +
KRAS is mutated in 0.63% of hepatocellular carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Clear Cell Renal Cell Carcinoma +
KRAS is mutated in 0.16% of clear cell renal cell carcinoma patients [3].
KRAS is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in clear cell renal cell carcinoma trials with KRAS alterations as inclusion criteria [4].
Double-Hit Lymphoma +
KRAS is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in double-hit lymphoma trials with KRAS alterations as inclusion criteria [4].
Juvenile Myelomonocytic Leukemia +
KRAS is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Azacitidine is the most frequent therapy in juvenile myelomonocytic leukemia trials with KRAS alterations as inclusion criteria [4].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
KRAS is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in myelodysplastic/myeloproliferative neoplasm, unclassifiable trials with KRAS alterations as inclusion criteria [4].
Peripheral T-Cell Lymphoma +
KRAS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in peripheral T-cell lymphoma trials with KRAS alterations as inclusion criteria [4].
Peritoneal Mesothelioma +
KRAS is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in peritoneal mesothelioma trials with KRAS alterations as inclusion criteria [4].
Pleural Mesothelioma +
KRAS is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in pleural mesothelioma trials with KRAS alterations as inclusion criteria [4].
Refractory Anemia With Excess Blasts +
KRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (1 open) [4].
Azacitidine is the most frequent therapy in refractory anemia with excess blasts trials with KRAS alterations as inclusion criteria [4].
Refractory Anemia With Excess Blasts-2 +
KRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and refractory anemia with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Binimetinib is the most frequent therapy in refractory anemia with excess blasts-2 trials with KRAS alterations as inclusion criteria [4].
Rhabdoid Tumor +
KRAS is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in rhabdoid tumor trials with KRAS alterations as inclusion criteria [4].
Schwannoma +
KRAS is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in schwannoma trials with KRAS alterations as inclusion criteria [4].
Secondary Acute Myeloid Leukemia +
KRAS is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Ect-001 expanded cord blood is the most frequent therapy in secondary acute myeloid leukemia trials with KRAS alterations as inclusion criteria [4].
Therapy-Related Acute Myeloid Leukemia +
KRAS is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Ect-001 expanded cord blood is the most frequent therapy in therapy-related acute myeloid leukemia trials with KRAS alterations as inclusion criteria [4].
Thymic Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with KRAS alterations as inclusion criteria [4].
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
What Is My Cancer Genome?
My Cancer Genome Data Sources
Legal Policies & Licensing
Letter from the Editors
About GenomOncology
How to Give to My Cancer Genome
Types of Molecular Tumor Testing
Circulating DNA
Detecting Gene Alterations in Cancers
Molecular Tumor Board
My Cancer Genome is managed by the
Vanderbilt-Ingram Cancer Center
Copyright © 2010 - 2017 MY CANCER GENOME


text:
Slip and Fall Attorney David S. Leigh, P.C., Discusses Manhattan's Most Common Injuries
Chelsea, NY: Each year, more than 2,000,000 slip and fall injuries occur in New York City. Residents need to be aware of their rights in the event that they are injured by a slippery sidewalk or any other hazardous surface.
David S. Leigh, a slip and fall attorney and founder of the Law Office of David S. Leigh, recently published an article about the most common slip and fall injuries in Manhattan. Even though it might seem minor, falls can cause serious injuries, especially for older people.
"Every year, more than one million Americans are injured in a fall. In the US, slips and falls are the most common cause of injury. They injure more than a thousand people each year and cost the US approximately 13 to 15 million annually." said the slip and fall attorney.
Most incidents in New York City that result from a slip or trip-and-fall, including those that can cause personal injury or death, are preventable. In these cases, the negligent party could be held responsible if they cause injuries or other damage.
These types of cases may involve a slip and fall due to an obstacle or other danger that was not properly addressed, resulting in injury to the victim. This is what a Manhattan personal injuries attorney may refer to as a "slip and fall" incident.
Accidents can occur in Chelsea Manhattan. Sometimes a fall can be just a simple fall, however, it could also lead to an unfortunate accident. Negligence is when someone else was responsible for the accident and it could have been prevented.
New York's premises liability law covers slip and fall and trip and fall injuries. The law states that the owner of a property may be held responsible for any injuries or accidents caused by unsafe pavement conditions.
Both private and public property owners have the responsibility of keeping their property safe, including the sidewalk. This is to protect anyone who may slip, trip, or fall on it. If they fail to do this, it could be considered carelessness and the responsible party may be held liable for any personal injuries.
Some injuries sustained in a slip-and-fall accident may heal with proper medical intervention. But some victims are permanently handicapped. Slip and fall injuries are responsible for more than 17,000 deaths per year, according to the CDC. It's almost 36 times less than that of cancer mortality, but could easily decrease and save thousands.
To learn more about slip and fall injuries and how David Leigh, P. C can help, visit the Law Office of David S. Leigh, P.C.'s website https://leighlawoffice.com/new-york-slip-and-fall-lawyer/trip-attorney-chelsea-manhattan/.
About the Law Office of David S. Leigh, P.C.
At the Law Office of David S. Leigh, P.C., their team of civil rights lawyers in New York diligently pursue discrimination wherever it happens, whether in the school system, the workplace, a law enforcement agency, or the prison system. In this country, under the laws, every person has the right to be treated lawfully and respectfully with the same rights as every other American.
For more information about David S. Leigh, Personal Injury Attorney and Car Accident Lawyer | Slip and Fall Law Firm, contact the company here:
David S. Leigh, Personal Injury Attorney and Car Accident Lawyer | Slip and Fall Law Firm
David S. Leigh
11 Broadway # 615, New York, NY 10004


text:
package jeo.games.cards.jass;

import jeo.games.cards.Constants;
import jeo.games.cards.objects.Card;
import jeo.games.cards.objects.Color;

public class JassCard
	extends Card
{
	////////////////////////////////////////////////////////////////////////////
	// ATTRIBUTE(S)
	////////////////////////////////////////////////////////////////////////////

	/**
	 * Generated serial version ID.
	 */
	private static final long serialVersionUID = 2598328382261446090L;

	////////////////////////////////////////////////////////////////////////////
	// CONSTRUCTOR(S)
	////////////////////////////////////////////////////////////////////////////

	public JassCard(final Color color, final int number)
	{
		super(color, number);
	}

	////////////////////////////////////////////////////////////////////////////
	// CARD
	////////////////////////////////////////////////////////////////////////////

	@Override
	public int getValue(final Color dominantColor, final Card card)
	{
		int value;
		final Color cardColor = card.getColor();
		switch (card.getNumber())
		{
			// Nombre 9 (ou nell)
			case 7:
				if (cardColor.equals(dominantColor))
				{
					value = 14;
				}
				else
				{
					value = 0;
				}
				break;
			// Nombre 10
			case 8:
				value = 10;
				break;
			// Valet (ou bourg)
			case 9:
				if (cardColor.equals(dominantColor))
				{
					value = 20;
				}
				else
				{
					value = 2;
				}
				break;
			// Dame
			case 10:
				value = 3;
				break;
			// Roi
			case 11:
				value = 5;
				break;
			// As
			case 12:
				value = 11;
				break;
			// Sinon
			default:
				value = 0;
		}
		return value;
	}

	@Override
	public int getPower(final Color dominantColor, final Card firstCard, final Card card)
	{
		int power;
		final Color firstCardColor = firstCard.getColor();
		final Color cardColor = card.getColor();
		power = card.getNumber();
		if (cardColor.equals(dominantColor))
		{
			switch (card.getNumber())
			{
				// Nell
				case 7:
					power = 13;
					break;
				// Bourg
				case 9:
					power = 14;
					break;
				default:
			}
			power += 2 * Constants.N_NUMBERS;
		}
		else if (cardColor.equals(firstCardColor))
		{
			power += Constants.N_NUMBERS;
		}
		return power;
	}
}


text:
Q: Find Duplicated Key in a complicated React component I have a react component, which generate many keys for a time, I am not sure which one is not unique. The error is as below. Any easy way to help debugging? thanks!
react.js:19500 Warning: Each child in an array or iterator should have a unique "key" prop. Check the render method of MyGrid. See https ://fb.me/ react-warning-keys for more information.

A: This is a warning that you have NOT assigned a key, rather than it isn't actually unique, the next line of the message should tell you exactly what is the offending element - see an example below in div (created by CardsComponent)
warning.js:36 Warning: Each child in an array or iterator should have a unique "key" prop. Check the render method of `CardsComponent`. See fb.me/react-warning-keys for more information.
    in div (created by CardsComponent)
If you want to debug further the test is done in ReactElementValidator.validateExplicitKey which simply does a check for if the element key being non null, no checking of uniqueness amongst sibling keys...
function validateExplicitKey(element, parentType) {
  if (!element._store || element._store.validated || element.key != null) {
    return;
  }
  // if it gets here it has failed and you will be warned

The interesting part here being element.key != null as the others pass as virtue of already having been validated

A: Click to expand the error in the console to reveal the stack trace. Follow the calls up to the one before createElementWithValidation and it should show you the culprit line number.
Log the keys you're using there. If there's a ton, put them in an array and [].filter((e, i, a) => a.indexOf(e) !== i)


text:
Q: If $X_n$ converges a.s. to $2$ , is $X_n$ integrable for large $n$? Let $(X_n)_{n\geq 1}$ be a sequence of random variables on a probability space $(\Omega, \mathcal F,P)$.
Assume that:

*

*$\forall n\geq 1, \forall \omega\in \Omega, X_n(\omega)\geq 0$,

*$(X_n)$ converges almost surely to $2$.

Is is true that $E[X_n]<\infty$ for $n$ large enough ?
I don't have any leads on this one (this question comes up naturally in my research), I'm guessing that an example where $E[X_n]=\infty$ can be found...
EDIT: the third condition was implied by the a.s. convergence, I've removed it.

A: As I said in the comments. You can take the Probability space to be $([0,1],\mathcal{B},\lambda)$ .
Take $$X_{n}(x)=2+\frac{1}{x}\cdot\mathbf{1}_{(0,\frac{1}{n})}$$
Then $X_{n}\to 2$ pointwise, but $E[X_{n}]=\infty\,,\forall n$ .


If you are looking for a quality used car serving the Phoenix metro area from a dealership you can trust, stop by Big Two Toyota at 1250 S. Gilbert Rd. in Chandler Arizona. We have a large inventory of pre-owned Toyota vehicles and used cars serving the Phoenix metro area customers at very affordable prices. Don't let these opportunities slip away!
Take a look at what we have currently on our used car lot. We take pride in offering quality used cars at our car dealership serving Chandler, Tempe, Mesa, and Gilbert, AZ. You can use our Power Search tools below to help make your decision easier. If you have any trouble finding the vehicle you are looking for, please try our CarFinder service and we'll find it for you!
At Big Two Toyota of Chandler, we provide more than just used cars. Our Toyota dealership in Chandler also offers onsite car loans and Toyota lease assistance, Toyota car parts, auto body repair & collision center and Toyota car repair service.
Pricing does not include taxes, license, title fees, insurance, or dealer documentation fee of $499. All pricing includes dealer installed options.